黄静,林欢,蒋巧颖,叶清清,吴伦

• 1:宁波大学附属第一医院药学部

摘要(Abstract)：

目的 分析新型抗肿瘤药物与抑酸药的相互作用，为临床合理用药提供参考。方法 通过Lexicomp数据库，对国家卫生健康委员会发布的《新型抗肿瘤药物临床应用指导原则（2022版）》中收录的新型抗肿瘤药物与抑酸药的相互作用进行逐一查询并分析。结果 根据Lexicomp数据库，厄洛替尼、达可替尼、达沙替尼、培唑帕尼和奈拉替尼与质子泵抑制剂/钾竞争性酸阻断剂（PPIs/PCABs）存在X级相互作用，应避免联用；吉非替尼、尼洛替尼和哌柏西利与PPIs/PCABs存在D级相互作用，建议调整治疗；索拉非尼，免疫检查点抑制剂纳武利尤单抗、帕博利珠单抗、度伐利尤单抗、阿替利珠单抗、伊匹木单抗与PPIs/PCABs存在C级相互作用，无需调整剂量；拉帕替尼、达拉非尼、塞瑞替尼、恩曲替尼、佩米替尼、索立德吉与PPIs/PCABs存在B级相互作用，不需要采取措施。达沙替尼、培唑帕尼与组胺H_2受体拮抗剂（H_2RAs）存在X级相互作用，应避免联用；吉非替尼、厄洛替尼、达可替尼、尼洛替尼、奈拉替尼与H2RAs存在D级相互作用，建议调整治疗；拉帕替尼和塞瑞替尼与H_2RAs存在B级相互作用，不需要采取措施。结论 新型抗肿瘤药物的治疗过程中应减少不必要的抑酸药的使用，以避免可能的药物相互作用。

关键词(KeyWords)： 新型抗肿瘤药物;抑酸药;质子泵抑制剂;钾离子竞争性酸阻滞剂;H_2受体阻断剂;药物相互作用

Abstract:

Keywords:

基金项目(Foundation): 宁波市卫生健康青年技术骨干人才项目（黄静）

作者(Author): 黄静,林欢,蒋巧颖,叶清清,吴伦

DOI: 10.19577/j.1007-4406.2023.05.010

参考文献(References)：

• [1] SMELICK G S, HEFFRON T P, CHU L, et al. Prevalence of acidreducing agents(ARA)in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development[J]. Mol Pharmaceutics, 2013, 10(11):4055.
• [2] PENG K N, CHEN K, TEPLY B A, et al. Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients[J]. Ann Pharmacother, 2022, 56(4):377.
• [3] PLASENCIA-GARCíA B O, RODRíGUEZ-MENéNDEZ G, RICORANGEL M I, et al. Drug-drug interactions between COVID-19treatments and antipsychotics drugs:integrated evidence from 4databases and a systematic review[J]. Psychopharmacology,2021, 238(2):329.
• [4]国家卫生健康委办公厅.国家卫生健康委办公厅关于印发新型抗肿瘤药物临床应用指导原则(2022年版)的通知(国卫办医政函[2022]465号)[EB/OL].(2022-12-30)[2023-02-17]. http://www.nhc.gov.cn/yzygj/s7659/202212/8df034c9afb44a9d95cd986d4e12fbd8.shtml.
• [5]徐银莹,陆子红,李琪,等.质子泵抑制剂对口服靶向抗肿瘤药物吸收影响的研究进展[J].中国药物警戒, 2021, 18(11):1091.
• [6] VAN LEEUWEN R W F, PERIC R, HUSSAARTS K G A M, et al.Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol,2016, 34(12):1309.
• [7] YAGO M R, FRYMOYER A, BENET L Z, et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria[J]. AAPS J, 2014, 16(6):1358.
• [8] BRAVE M, GOODMAN V, KAMINSKAS E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate[J]. Clin Cancer Res, 2008, 14(2):352.
• [9] KEYVANJAH K, DIPRIMEO D, LI A, et al. Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects[J]. Br J Clin Pharmacol, 2017, 83(3):554.
• [10] TAN A R, GIBBON D G, STEIN M N, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors[J]. Cancer Chemother Pharmacol, 2013, 71(6):1635.
• [11] TANG W F, TOMKINSON H, MASSON E. Effect of sustained elevated gastric pH levels on gefitinib exposure[J]. Clin Pharmacol Drug Dev, 2017, 6(5):517.
• [12] YOKOTA H, SATO K, OKUDA Y, et al. Effects of histamine2-r e c e p t o r a n t a g o n i s t s a n d p r o t o n p u m p i n h i b i t o r s o n t h e pharmacokinetics of gefitinib in patients with non-small-cell lung cancer[J]. Clin Lung Cancer, 2017, 18(6):e433.
• [13] YIN O Q P, GALLAGHER N, FISCHER D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib[J]. J Clin Pharmacol, 2010, 50(8):960.
• [14] YIN O Q P, BéDOUCHA V, MCCULLOCH T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers[J]. Cancer Chemother Pharmacol,2013, 71(1):219.
• [15] SUN W, KLAMERUS K J, YUHAS L M, et al. Impact of acidreducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions[J]. Clin Pharmacol Drug Dev, 2017, 6(6):614.
• [16] TAKAHASHI N, MIURA M, NIIOKA T, et al. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients[J]. Cancer Chemother Pharmacol, 2012, 69(4):999.
• [17] SAKAMOTO S, SATO K, TAKITA Y, et al. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib[J]. Investig N Drugs, 2020, 38(6):1687.
• [18] FANG Y H, YANG Y H, HSIEH M J, et al. Concurrent protonpump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide populationbased study[J]. Cancer Manag Res, 2019, 11:8539.
• [19] SHARMA M, HOLMES H M, MEHTA H B, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors:prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer[J]. Cancer, 2019, 125(7):1155.
• [20] ZENKE Y, YOH K, MATSUMOTO S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations[J]. Clin Lung Cancer, 2016, 17(5):412.
• [21] YIN O Q P, GILES F J, BACCARANI M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia[J].Cancer Chemother Pharmacol, 2012, 70(2):345.
• [22] VAN DE SIJPE G, BEUSELINCK B, VAN NIEUWENHUYSE T,et al. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma[J]. Eur J Clin Pharmacol, 2020, 76(9):1273.
• [23] KOSTINE M, MAURIC E, TISON A, et al. Baseline comedications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events[J].Eur J Cancer, 2021, 157:474.
• [24] RUANGLERTBOON W, SORICH M J, LOGAN J M, et al. The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib[J]. J Cancer Res Clin Oncol, 2020, 146(10):2693.